‘Wildcard’ Patents: Why A REVAMP-ed Proposal Might Work In 2017

Before election day, the idea of a new transferrable exclusivity incentive seemed like an extreme long shot for enactment. But now advocates think it has a real chance – and a strategy to redraft the idea to answer Democratic critics and avoid a high CBO score.

Red and blue arrow elevators with businessmen going up and down.

It didn’t take long for an audience of public health professionals focused on antibiotic resistance to find a silver lining in the Nov. 8 election results: the GOP victories mean that there is a very real chance for enactment of a “wildcard” patent extension to support development of drugs for emerging infections.

The organizers of a Nov. 9 Duke Margolis Center workshop on incentives for antibiotic development probably expected a very different...

More from Legislation

More from Pink Sheet

Anti-Vaccine Activists Among New US CDC Vaccine Advisors

 

HHS Secretary Kennedy's new ACIP appointments include multiple members of anti-vaccine groups and people who have spread misinformation about COVID-19 vaccines.

US FDA May Consolidate Support Services After Extensive Cuts

 

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

US FDA’s Rising First-Cycle Complete Response Rate Draws Congress’ Attention

 
• By 

The House Appropriations Committee wants an analysis of how issues that led to CRLs could have been resolved within the first review cycle and seeks an agency crackdown on counterfeit GLP-1 agonists.